Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Dysphagia in Medullary Infarction
NCT06196606Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in dysphagia, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Functional Oral Intake Scale at Day 180 and Rosenbek Penetration-Aspiration Scale at Day 14. Started Nov 2022; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
dysphagia
Beyond the preview
Go deeper on NCT06196606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196606.